Dr. med. Andreas Wilke Dr. med. Andrej Malazhavy und Detelin Lalev Denchev Fachaerzte Innere Medizin und Kardiologie Partnerschaft — Clinical Trial Site

17 Registered trials

6 Currently recruiting

Organisation

Dr. med. Andreas Wilke Dr. med. Andrej Malazhavy und Detelin Lalev Denchev Fachaerzte Innere Medizin und Kardiologie Partnerschaft

Location

Papenburg, Germany

Identifier

ORG-100044809

Address

Kirchstrasse 9, Papenburg-Untenende, 26871, Germany

Departments

#2109: Kardiologie Papenburg
#3218:Praxis
2343:Kardiologische Praxis Papenburg
Fachaerzte Innere Medizin und Kardiologie Partnerschaft
Gemeinschaftspraxis Papenburg
Kardiologiesche Gemeinschaftspraxis
Kardiologische Gemeinschaftspraxis Papenburg
Kardiologische Praxis Papenburg
N/A
NA
Practice

Clinical trials at this site (17)

Search interface

OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending

2025-520554-11-00 Cardiovascular Disease 5
HF-POLARIS: A research study to look at how well NNC0487-0111 works compared to placebo in people with heart failure and obesity Recruiting

2025-523717-29-00 HFpEF or HFmrEF and obesity 5 2026-04-28
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting

2024-516652-18-00 Atherosclerotic cardiovascular disease (ASCVD) and obes 5 2025-10-10
A Trial to Test How AZD0780 Affects Serious Heart, Stroke, or Vascular Problems in Patients with Heart, Stroke or Vascular Disease or at Hig… Recruiting

2025-520519-14-00 Atherosclerotic Cardiovascular Disease 5 2025-09-03
A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure and a weak pumping functio… Recruiting

2024-519525-38-00 Heart failure 5 2025-08-22
A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Recruiting

2023-509706-30-00 Heart failure (HF) 5 2024-10-18
A clinical trial to learn more about the effects of DII235 in people with high levels of lipoprotein(a) Ended

2025-521912-21-00 Cardiovascular risk reduction in participants with elev 4 2026-01-26
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended

2023-508630-34-00 Overweight 5 2024-05-28
OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended

2022-501608-85-00 Cardiovascular disease (atherosclerotic cardiovascular 5 2023-05-09
HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended

2022-501939-16-00 Heart failure (HF) with mildly reduced ejection fractio 5 2023-05-09
A Phase 2 Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejec… Ended

2023-508736-62-00 Heart failure (HF) with reduced ejection fraction (HFrE 4 2024-08-08
A Phase 2 Clinical Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Preserved Ejecti… Ended

2023-508737-13-00 chronic heart failure 4 2024-08-08
A randomized, multicenter, open-label trial comparing the effectiveness of Inclisiran to bempedoic acid on LDL cholesterol (LDL-C) lowering … Ended

2024-511076-32-00 Hypercholesterolemia 6 2024-06-21
A proof of concept and dose-finding study of XXB750 in patients with heart failure Ended

2023-504678-39-00 Heart Failure 4 2024-03-13
Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol,is safe and can have an impact on patient quality of … Ended

2024-511263-28-00 Hypercholesterolemia 6 2022-04-08
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended

2023-503673-38-00 Adults at high risk of cardiovascular events without pr 5 2019-05-24